SCHEMBL6412970

SCHEMBL6412970

Oc1cccc(C=NNc2nc3nonc3nc2Nc2ccc(Cl)c(Cl)c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.46
GAA P10253 5/20 0.46
SMN1; SMN2 Q16637 8/20 0.43
TP53 P04637 3/20 0.43
CCR2 P41597 1/20 0.43
CCR5 P51681 1/20 0.43
MEN1 O00255 7/20 0.43
KMT2A Q03164 7/20 0.43
RAB9A P51151 5/20 0.43
NPC1 O15118 4/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
KDM4E B2RXH2 3/20 0.43
LMNA P02545 3/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
POLB P06746 3/20 0.41
PKM P14618 2/20 0.41
THRB P10828 1/20 0.40
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6440252 0.91 MAPT (0.44) MAPTGAASMN1; SMN2TP53CCR2
SCHEMBL6431153 0.89 MAPT (0.47) MAPTGAASMN1; SMN2TP53CCR2
SCHEMBL6432172 0.89 GAA (0.47) MAPTGAASMN1; SMN2TP53CCR2
SCHEMBL6435303 0.86 BIRC5 (0.48) MAPTGAASMN1; SMN2TP53CCR2
SCHEMBL6414699 0.86 MAPT (0.46) MAPTGAASMN1; SMN2TP53MEN1
SCHEMBL6420018 0.85 MAPT (0.51) MAPTGAASMN1; SMN2TP53MEN1
SCHEMBL6416491 0.84 MEN1 (0.49) MAPTGAASMN1; SMN2TP53CCR2
SCHEMBL6431965 0.81 MAPT (0.52) MAPTGAASMN1; SMN2MEN1KMT2A
SCHEMBL6431957 0.81 MAPT (0.52) MAPTGAASMN1; SMN2MEN1KMT2A
SCHEMBL6432225 0.80 GAA (0.44) MAPTGAASMN1; SMN2TP53CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885GAA 3186/4885SMN1; SMN2 4369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.